Astellas Announces Opening of Phase 1b Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ASP0367

On Sept. 1, 2022, Astellas announced that their Phase 1b study is now open at sites across the United States. They will be adding more sites as they become ready to accept new participants. 

The primary purpose of the study is to evaluate the safety and tolerability, and to evaluate how the body processes ASP0367 and how it affects muscle function.

Please download and read their Community Newsletter below.